

LIST OF REFERENCES CITED BY APPLICANT				ATTY. DOCKET NO. 12560-016-999		APPLICATION NO. 10/759,561	
				APPLICANT Weiner <i>et al.</i>			
				FILING DATE January 15, 2004		GROUP ART UNIT 1617	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	NAME		TRANSLATION
	B01	JP 51052176	5/08/76	Yoshitomi Pharmaceut Ind		English abstract provided.
	B02	JP 5208517 A	7/15/77	Yoshitomi Pharmaceut Ind Ltd		English abstract provided.
	B03	WO 02/24649	3/28/02	Acetelion Pharmaceuticals, Ltd.		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C01	Borman <i>et al.</i> , "5-HT _{2B} receptors play a key role in mediating the excitatory effects of 5-HT in human colon <i>in vitro</i> ," <i>Br. J. Pharmacol.</i> , Vol. 135, No. 5, pp. 1144-51 (2002)
	C02	Choi <i>et al.</i> , "5HT _{2B} receptor-mediated serotonin morphogenic functions in mouse cranial neural crest and myocardiac cells," <i>Development</i> , Vol. 124, pp. 1745-1755, (1997)
	C03	Cox, R., "Medicinal Chemistry- 28 th International Symposium: 8-12 June 2002, San Diego, CA, USA," <i>IDrugs</i> , Vol. 5, No. 7, pp. 626-632 (2002)
	C04	Fitzgerald <i>et al.</i> , "Possible Role of Vavular Serotonin 5-HT _{2B} Receptors in the Cardiopathy Associated with Fenfluramine," <i>Molecular Pharmacol.</i> Vol. 57, pp. 75-81 (1999)
	C05	Glazer, W.M., "Extrapryramidal side effects, tardive dyskinesia, and the concept of atypicality," <i>J. Clin. Psychiatry</i> , Vol. 61, Supp. 3, pp. 16-21 (2000)
	C06	Ito <i>et al.</i> , "Prediction of Human Drug Clearance from <i>in Vitro</i> and Preclinical Data Using Physiologically Based and Emperical Approaches," <i>Pharm. Res.</i> , Vol. 22, No. 1, pp. 103-12 (2005)
	C07	Johnston <i>et al.</i> , "Drugs in Development for Parkinson's Disease: An Update," <i>Current Opin. Investig. Drugs</i> , Vol. 7, No. 1, pp. 25-32 (2006)
	C08	Kay, G.G., "The effects of antihistamines in cognition and performance," <i>J. Allergy Clin. Immunol.</i> , Vol. 105, No. 6, Pt. 2, pp. S622-27 (2000)
	C09	Maubach, K., "Psychiatric Drug Discovery and Development," <i>Expert Opin. Investig. Drugs.</i> , Vol. 12, No. 9, pp. 1571-1575 (2003)
	C10	Meltzer <i>et al.</i> , "Serotonin Receptors: Their Key Role in Drugs to Treat Schizophrenia," <i>Progress in Neuro-Psychopharmacology & Biol. Psych.</i> , Vol. 27, pp. 1159-1172 (2003)
	C11	Morgan <i>et al.</i> , "Emerging Drugs for Parkinson's Disease," <i>Expert Opin. Emerging Drugs.</i> , Vol. 11, No. 3, pp. 403-417 (2006)
	C12	Naritomi <i>et al.</i> , "Prediction of human hepatic clearance from <i>in vivo</i> animal experiments and <i>in vitro</i> metabolic studies with liver microsomes from animals and humans," <i>Drug Metab. Dispos.</i> , Vol. 29, No. 10, pp. 1316-24 (2001)
	C13	Negibil <i>et al.</i> , "Serotonin 2B receptor is required for heart development," <i>PNAS</i> , Vol. 97, No. 17, pp. 9508-13 (2000)
	C14	Negibil <i>et al.</i> , "Ablation of Serotonin 5-HT _{2B} Receptors in Mice Leads to Abnormal Cardiac Structure and Function," <i>Circulation</i> , Vol. 103, pp. 2973-79 (2001)
	C15	Negibil <i>et al.</i> , "Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT _{2B} -receptor signaling," <i>FASEB J.</i> , Vol. 27, No. 10, pp. 1373-75 (2003)

	C16	Obach <i>et al.</i> , "The Prediction of Human Pharmacokinetic Parameters from Preclinical and <i>In Vitro</i> Metabolism Data," <i>J. Pharm. Exp. Therap.</i> , Vol. 283, No. 1, pp. 46-58 (1997)
	C17	Roberts, C. "Drug Evaluation: ACP-103, a 5-HT _{2A} Receptor Inverse Agonist," <i>Current Opin. Investig. Drugs</i> , Vol. 7, No. 7, pp. 653-660 (2006)
	C18	Scriabine, A., "Psychiatric Drug Discovery and Development," <i>CNS Drug Rev.</i> , Vol. 9, No. 3, pp. 319-326 (2003)
	C19	Sica, D.A., "Alpha ₁ -Adrenergic Blockers: Current Usage Considerations," <i>J. Clin. Hypertension</i> , Vol. 7, pp. 757-62 (2005)
	C20	Stoner <i>et al.</i> , "Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery," <i>Int. J. Pharm.</i> , Vol. 269, No. 1, pp. 241-49 (2004)
	C21	Vanover <i>et al.</i> , "ACP-103, A 5-HT _{2A} Receptor Inverse Agonist, A Novel Potential Treatment For Psychosis," <i>Schizophrenia Research</i> , Vol. 60, No. 1, Supp. [S], p. 317 (2003)
	C22	Vanover <i>et al.</i> , "ACP-103, A 5-HT _{2A} Receptor Inverse Agonist: Safety, Tolerability and Pharmacokinetics in Healthy Volunteers," <i>International J. Neuropsychopharmacology</i> , Vol. 7, No. Supp. 2, pp. S253 (2004)
	C23	Vanover <i>et al.</i> , "Pharmacological Characterization of AC-90179 [2-(4-Methoxy-phenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidiny-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist," <i>J. Pharmacology & Experimental Therapeutics</i> , Vol. 310, No. 3, pp. 943-951 (2004)
	C24	Vanover <i>et al.</i> , "Pharmacological and Behavioral Profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R, 3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine 2A Receptor Inverse Agonist," <i>J. Pharmacology & Experimental Therapeutics</i> , Vol. 317, No. 2, pp. 910-918 (2006)
	C25	Wirshing <i>et al.</i> , "Novel Antipsychotics: Comparison of Weight Gain Liabilities," <i>J. Clin. Psychiatry</i> , Vol. 21, No. 6, pp. 579-87 (1999)
	C26	R & D Focus Drug News, Vol. 9, No. 3, pp. 1-12 (January 24, 2000)
	C27	R & D Focus Drug News, Vol. 10, No. 44, pp. 1-6 (November 12, 2001)
	C28	Office Action dated August 22, 2007 in Application No. 11/122,293, filed May 4, 2005.
	C29	Letter in response to Written Opinion of the Preliminary Examining Authority in PCT/US2004/001234, dated March 14, 2005.
	C30	Reply to Communication in European Patent Application No. 04702584.6-2123, dated August 16, 2006.
	C31	Reply to Communication in European Patent Application No. 04702584.6-2123, dated May 4, 2007.
	C32	Written Opinion of the Preliminary Examining Authority in in PCT/US2004/001234, dated December 15, 2004.
	C33	Official Communication in European Patent Application No. 04702584.6-2123, dated April 5, 2006.
	C34	Official Communication in European Patent Application No. 04702584.6-2123, dated February 23, 2007.

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MEPE 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	